eXIthera Pharmaceuticals
Westborough
About eXIthera Pharmaceuticals
ExIthera Pharmaceuticals is a developer of an early-stage biotechnology platform used to develop small-molecule pharmaceuticals. The company's stroke prevention and antithrombosis drugs are based on the unique pathophysiological role of Factor XI in the initiation of intravascular thrombi without causing undue bleeding. It focuses on developing stroke prevention and anti-thrombosis drugs based on Factor XI, which has a pathophysiological role in the initiation of intravascular thrombi without causing undue bleeding, enabling physicians to treat serious consequences, including venous thromboembolism, deep vein thrombosis, stroke, and heart attack.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $18.0M
- Funding stage: M&A
- Last round: Series Unknown (Aug 2017)
- Website: exithera.com
- Phone: +1 508 983 1436
Industries & Categories
Biotechnology, Genetics, Health Care, Medical, Pharmaceutical
Canonical: https://fsome.com/organization/exithera-pharmaceuticals-49245 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.